Acarix (ACARIX) Q1 2026 earnings summary

Executive summary

• Revenue grew 40% year-over-year to SEK 2,424 thousand, with U.S. revenue up 63% and 90% growth on a constant currency basis.

• Delivered 29 CADScor Systems in the U.S., a 53% increase from last year, reflecting accelerated adoption in primary care.

• Achieved EU MDR/CE MDR certification for CADScor System, supporting global market access and expansion.

• Clinical trials and ACC.26 data demonstrated significant cost savings, high negative predictive value, and operational benefits.

• Maintained operational functionality despite geopolitical tensions, with positive cash flow from operating activities of SEK 1,113 thousand.

Financial highlights

• Global revenue increased 40% year-over-year to SEK 2,424 thousand, with U.S. patch sales up 15% and 122 boxes sold.

• Gross margin remained strong at 81%, above med tech industry benchmarks.

• Operating costs decreased 32% year-over-year to SEK 10,421 thousand, improving net loss by 38% to SEK -8,781 thousand.

• Monthly cash burn reduced by 21%, now at SEK 3,059 thousand per quarter.

• Cash balance at quarter-end was SEK 25,793 thousand, with equity at SEK 36,956 thousand.

Outlook and guidance

• Anticipates regulatory approval in Saudi Arabia and GCC countries in Q3 2026, with ongoing international expansion and new partnerships.

• Focused on expanding U.S. reimbursement, leveraging the Rural Health Transformation Program, and converting system placements into broader clinical adoption.

• Advancing U.S. performance trial and preparing for CMS CPT 1 transition.

• Growth plan may require additional financing later in 2026.

• Aims to achieve break-even and profitability in the near term.